Micromet has published a study in the recent issue of Molecular Immunology (2006; 43: 1183-1193) (1) explaining why large amounts of antibodies are needed to achieve a therapeutic effect in cancer patients. Each treatment cycle requires substantial amounts of antibodies per patient – typically in the gram range – although such antibodies appear quite potent in cell culture experiments. Micromet researchers have now performed cell culture experiments in the presence of human serum investigating both trastuzumab (Herceptin®) and Micromet’s human anti-Ep-CAM antibody adecatumumab (MT201).
